London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Evaluation of aqueous endocan and endostatin levels in patients with pseudoexfoliation syndrome

Poster Details

First Author: R.Yagci TURKEY

Co Author(s):    E. Guler   S. Dervisogullari   F. Kazanci   S. Gok   Y. Totan   I. Hepsen

Abstract Details


The purpose of the present study was to evaluate the aqueous humor endocan and endostatin levels in patients with and without pseudoexfoliation (PEX) syndrome


Turgut Ozal University Hospital, Ankara, Turkey


Endocan and endostatin levels were determined in 29 cataract patients with PEX and in 32 cataract patients without PEX, by enzyme-linked immunosorbent assay


The aqueous levels of endocan in patients with PEX (26.39 ± 5.81 pg/ml) was significantly higher than in the control group (11.42 ± 2.45 pg/ml) (p= 0.046). Regarding the aqueous levels of endostatin, it was lower in PEX (12.00 ± 1.36 pg/ml) compared to control group (14.22 ± 3.32 pg/ml), however, the difference was not statistically significant (p= 0.87)


The increased levels of aqueous endocan, as markers of inflammation and endothelial dysfunction, may play a role in PEX pathogenesis. Additionally, endostatin as an endogenous inhibitor of neovascularization and regulator of vascular endothelial cell migration and matrix turnover was lower in aqueous of patients with PEX but not statistically significant. Their potential as a therapeutic target needs to be evaluated in further studies FINANCIAL INTEREST: NONE

Back to Poster listing